Lactobacillus reuteri ATCC55730 in cystic fibrosis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 58, Issue 1, 2014, Pages 81-86

  Di Nardo, Giovanni ^a   Oliva, Salvatore ^a   Menichella, Alessandra ^b   Pistelli, Riccardo ^c   Biase, Riccardo Valerio De ^b   Patriarchi, Francesca ^b   Cucchiara, Salvatore ^a   Stronati, Laura ^d  

^a Department of Pediatrics   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^d ENEA   (Italy)

Author keywords

cystic fibrosis; Lactobacillus reuteri; probiotics

Indexed keywords

CALGRANULIN; CYTOKINE; INTERLEUKIN 8; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; BACTERIAL COLONIZATION; BURKHOLDERIA CEPACIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL INFECTION; HEMOPTYSIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LACTOBACILLUS REUTERI; MALE; MYCOBACTERIUM; NONHUMAN; OTITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

BURKHOLDERIA CEPACIA; CORYNEBACTERINEAE; LACTOBACILLUS REUTERI;

ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; DNA-BINDING PROTEINS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASES; HOSPITALIZATION; HUMANS; INTERLEUKIN-8; LACTOBACILLUS REUTERI; LEUKOCYTE L1 ANTIGEN COMPLEX; LUNG; LUNG DISEASES; MALE; NUCLEAR PROTEINS; NUMBERS NEEDED TO TREAT; PROBIOTICS; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84893657254     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000187     Document Type: Article

References (61)

1. Ratjen F, McColley SA. Update in cystic fibrosis 2011. Am J Respir Crit Care Med 2012;185:933-6.
2. Brugha RE, Davies JC. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and new treatments. Br J Hosp Med (Lond) 2011;72: 614-9.
3. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011;9:32.
4. Raia V, Maiuri L, de Ritis G, et al. Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res 2000;47:344-50.
5. Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 2004;20:813-9.
6. Infante Pina D, Redecillas Ferreiro S, Torrent Vernetta A, et al. Improvement of intestinal function in cystic fibrosis patients using probiotics. Ann Pediatr (Barc) 2008;69:501-5.
7. Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004;CD003048.
8. Guandalini S. Probiotics for children with diarrhea: an update. J Clin Gastroenterol 2008;42:53-7.
9. Isolauri E, Arvola T, Sutas Y, et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000;30:1604-10.
10. Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003;111:389-95.
11. Kalliomaki M, Salminen S, Poussa T, et al. Probiotics and prevention of atopic disease: 4-years follow-up of a randomised placebo-controlled trial. Lancet 2003;361:1869-71.
12. Elahi B, Nikfar S, Derakhshani S, et al. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008;53:1278-84.
13. Neil FR, Albert DL. Probiotics in the treatment of human inflammatory bowel diseases: update 2008. J Clin Gastroenterol 2008;42:97-103.
14. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic E. coli vs. mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
15. Hatakka K, Savilahti E, Ponka A, et al. Effect of long term consumption of probiotic milk on infection in children attending day care centres: double blind, randomised trial. Br Med J 2001;322:1327.
16. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005;115:5-9.
17. Hojsak I, Abdovic S, Szajewska H, et al. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratoty tract infections. Pediatrics 2010;125:1171-7.
18. Rosenfeldt V, Belfeldt E, Valerius NH, et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 2004;145:612-6.
19. Perdigon G, Fuller R, Raya R. Lactic acid bacteria and their effect on the immune system. Curr Issues Interest Microbiol 2001;1:27-42.
20. Di Caro S, Tao H, Grillo A, et al. Effects of Lactobacillus GG on genes expression pattern in small bowel mucosa. Dig Liver Dis 2005;37:320-9.
21. Van Elburg RM, Uil JJ, Van Aalderen WMC, et al. Intestinal permeability in exocrine pancreatic insufficiency due to cystic fibrosis or chronic pancreatitis. Pediatr Res 1996;39:985-91.
22. Claeys S, Van Hoecke H, Holtappels G, et al. Nasal polyps in patients with and without cystic fibrosis: a differentiation by innate markers and inflammatory mediators. Clin Exp Allergy 2005;35:467-72.
23. Bruzzese E, Raia V, Spagnuolo MI, et al. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr 2007;26:322-8.
24. Weiss B, Bujanover Y, Yahav Y, et al. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol 2010;45:536-40.
25. Microbiology and Infectious Disease in Cystic Fibrosis. Consensus Conferences: Concept in Care. Vol V, Sect 1. Bethesda, MD: Cystic Fibrosis Foundation; 1994.
26. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94.
27. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spiro-metry. Eur Resp J 2005;26:319-38.
28. Henig NR, Tonelli MR, Pier MV, et al. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 2001;56:306-11.
29. Reeinhardt N, Chen CIU, Loppow D, et al. Cellular profile of induced sputum in children with stable cystic fibrosis: comparison with BAL. Eur Resp J 2003;22:497-502.
30. Fagerberg UL, Loof L, Merzoug RD, et al. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastro-enterol Nutr 2003;37:468-72.
31. Olafsdottir E, Aksnes L, Fluge G, et al. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002;91:45-50.
32. Thomas DW. Greer Fr and Committee on Nutrition: Section on Gastro-enterology, Hepatology, and Nutrition. Clinical report: probiotics and prebiotics in pediatrics. Pediatrics 2010:1217-31.
33. Gerritsen J, Smidt H, Rijkers GT, et al. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 2011;6:209-40.
34. Ruemmele FM, Bier D, Marteau P, et al. Clinical evidence for im-munomodulatory effects of probiotic bacteria. J Pediatr Gastroenterol Nutr 2009;48:126-41.
35. Savino F, Pelle E, Palumeri E, et al. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007;119:124-30.
36. Indrio F, Riezzo G, Raimondi F, et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Invest 2011;41:417-22.
37. Valeur N, Engel P, Carbajal N, et al. Colonization and immunomodula-tion by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol 2004;70:1176-81.
38. Liu Y, Fatheree NY, Mangalat N, et al. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2010;299:G1087-96.
39. Ma D, Forsythe P, Bienenstock J. Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun 2004;72:5308-14.
40. Livingston M, Loach D, Wilson M, et al. Gut commensal Lactobacillus reuteri 100-23 stimulates an immunoregulatory response. Immunol Cell Biol 2010;88:99-102.
41. Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Alimet Pharmacol Ther 2012;35:327-34.
42. Werlin SL, Benury-Silbiger I, Kerem E, et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010;51:304-8.
43. DuPont AW, DuPont HL. The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol 2011;8:523-31.
44. Forsythe P. Probiotics and lung diseases. Chest 2011;139:901-8.
45. Harata G, He F, Kawase M, et al. Differentiated implication of Lacto-bacillus GG and L. gasseri TMC0356 to immune responses of murine Peyer's patch. Microbiol Immunol 2009;53:475-80.
46. Koizumi S, Wakita D, Sato T, et al. Essential role of Toll-like receptors for dendritic cell and NK1.1(+) cell-dependent activation of type 1 immunity by Lactobacillus pentosus strain S-PT84. Immunol Lett 2008; 120:14-9.
47. Fink LN, Zeuthen LH, Christensen HR, et al. Distinct gut-derived lactic acid bacteria elicit divergent dendritic cell-mediated NK cell responses. Int Immunol 2007;19:1319-27.
48. Hao Q, Lu Z, Dong BR. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2011;CD006895.
49. Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy-a randomized, double-blind, placebo-controlled study. Br J Nutr 2009;101:1722-6.
50. Volsko TA. Cystic fibrosis and the respiratory therapist: a 50-year perspective. Respir Care 2009;54:587-94.
51. Moeller A, Stampfili SF, Rueckert B, et al. Effects of short-term rehabilitation program on airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2010;45:541-51.
52. Ordonez CL, Stulbarg M, Grundland H, et al. Effect of clarithro-mycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001; 32:29-37.
53. Al-Saleh S, Dell SD, Grasemann H, et al. Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr 2010; 157:1006-11.
54. Smountas AA, Lands LC, Mohammed SR, et al. Induced sputum in cystic fibrosis: within-week reproducibility of inflammatory markers. Clin Biochem 2004;37:1031-6.
55. Ordonez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Med 2003;168:1471-5.
56. Reinhardt N, Chen CI, Loppow D, et al. Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison with BAL. Eur Respir J 2003;22:497-502.
57. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004;56:515-48.
58. Aria V, Maiuri L, Ciacci C, et al. Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis. Thorax 2005;60:773-80.
59. Taggert C, Choicely RJ, Greally P, et al. Increased elastase release by CF neutrophilsis mediated by tumor necrosis factor-a and interleukin-8. Am J Physiol Lung Cell Mol Physiol 2000;278:L33-41.
60. Boncoeur E, Criq VS, Bonvin E, et al. Oxidative stress induces extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase in cystic fibrosis lung epithelial cells: potential mechanism for excessive IL-8 expression. Int J Biochem Cell Biol 2008;40:432-46.
61. Ranganathan SC, Parsons F, Gangell C, et al. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax 2011;66:408-13.